Dr. Rosenthal is a scientific advisor to Arch. He served as a director of Arch Therapeutics from June 2013 until May 2015 and as Chairman of the Board of Arch Biosurgery from April 2011 until June 2013. Having filled senior research and product development executive roles for medical technology companies for over 40 years, he successfully directed commercialization efforts for hundreds of novel medical products. He was Chief Scientific Officer at Boston Scientific from January, 1994 to January, 2005, Vice President of Research and Development at Johnson and Johnson Medical Products, Inc. from April, 1990 to January, 1994 and more recently Chief Executive Officer of two start-up companies, Labcoat, Ltd. and Cappella, Inc., both developing cardiovascular medical devices. He has been a Professor of Practice in Translational Research in Boston University's College of Engineering since January 2010, where he oversees biomedical engineering innovation. Dr. Rosenthal received his PhD in biochemistry from the University of Massachusetts, Amherst, 1973. Currently, Dr. Rosenthal serves as Non-Executive Director and as Chairman of the Compensation Committee and member of the Audit Committee for Cyberonics, Inc. (NASDAQ: CYBX), having joined its Board of Directors in January 2007. Dr. Rosenthal is a valuable asset to Arch because of his high-ranking roles in private and public medical device companies, his extensive experience overseeing research and development and commercialization of a large number of products in the medical field, and his company-building acumen.
Dr. Ellis-Behnke is the Director of the Nanomedicine Translational Think Tank at the Medical Faculty Mannheim of the University of Heidelberg in Germany. In addition, he holds affiliate faculty positions at M.I.T., as well as Wake Forest and University of South Florida medical schools. His research is focused on reconnecting the disconnected parts of the brain—with the goal of being able to provide a prescription to restore quality of life after brain or spinal cord trauma, or stroke. In animals he was the first to repair the brain showing reversal of blindness; to stop bleeding in less than 15 seconds without clotting; to preserve stem cells; and to immobilize prostate cancer stem cells. Previously, he was Associate Professor in the Faculty of Medicine at the University of Hong Kong, as well as Associate Director of the Technology Transfer Office. Prior to returning to school to pursue his PhD, Ellis-Behnke held various management positions including Senior Vice President of Huntingdon, a public company for pharmaceutical testing and consulting services; and in 1995 was co-founder/CEO of one of the first internet companies in the world to do online commerce. Ellis-Behnke is an Associate Editor for the journal Nanomedicine and is on the Editorial Board of Nanomedicine & Biotherapeutic Discovery. He is a member of the International Society of Nanomedicine and the Scientific Advisory Board of the Glaucoma Foundation. He has multiple worldwide patent applications and his “Nano Neuro Knitting” and “Immediate Hemostasis” technologies have each been licensed to companies for translation to humans. Technology Review named his “Nanohealing” discoveries one of the “Top 10 Emerging Technologies.” Ellis-Behnke received a PhD from MIT in Neuroscience; a Bachelor of Science from Rutgers University and graduated from Harvard Business School’s Advanced Manager’s Program (AMP).
John Richards, DPhil., who started advising Arch Therapeutics in 2016, bringing over 30 years of pharmaceutical industry and peptide chemistry experience. Since 2009, he has been Vice President of Global Pharmaceutical Development at The Medicines Company, responsible for CMC development and manufacturing of all the company’s products, including the very large scale program for the peptide-based anticoagulant, Angiomax®. He has extensive experience leading CMC programs which have resulted in the successful filing and approval of drugs and biologics in the United States, European
Previous roles included Director of Process Development at ImmuLogic Pharmaceutical Corporation, where he was responsible for the design, construction and operation of a multi-train peptide manufacturing facility, and Manager of Peptide Synthesis at UK start-up Cambridge Research Biochemicals and its
He earned his doctorate developing protecting groups for use in peptide synthesis at The University of Oxford. While performing his Post-Doctoral work in the Laboratory of Molecular Biology, Cambridge, UK, he was a member of Dr. Robert Sheppard's team that developed the Fmoc-solid phase method of peptide synthesis.
Robert M. Williams, PhD, an advisor to Arch since 2010, is a University Distinguished Professor at Colorado State University. Dr. Williams earned his B.A. degree in Chemistry from Syracuse University in 1975 and obtained his PhD degree in 1979 from MIT. He was a post-doctoral fellow at Harvard University (1979-80) prior to joining the faculty at Colorado State University in 1980 and is now a University Distinguished Professor. He has been a visiting Professor at the University of California, Berkeley (1990) and Harvard University (1994-95). Dr. Williams research interests utilize the tools of organic synthesis to study problems in chemical biology and medicinal chemistry. Williams has judiciously deployed total synthesis to interrogate hypotheses concerning the biomechanism and/or biosynthesis of complex, biologically significant natural products. Much of Williams’ recent work on complex alkaloid and peptide synthesis is based on his development of a practical and commercialized technology for the asymmetric synthesis of a-amino acids, peptide isosteres, peptides and depsipeptides. Dr. Williams has received several Honors and Awards including the NIH Research Career Development Award, The Eli Lilly Young Investigator Award, Fellow of the Alfred P. Sloan Foundation, the Merck, Academic Development Award, the Japanese Society for the Promotion of Science Fellowship, the ACS Arthur C. Cope Scholar Award and the ACS Ernest Guenther Award in the Chemistry of Natural Products. He serves on the Editorial Board of Chemistry & Biology; served as Editor for the journal Amino Acids (1991~1998) and is a Series co-Editor for The Organic Chemistry Series, (Elsevier). Dr. Williams has been a Founding Scientist for several biopharmaceutical companies including Microcide Pharmaceuticals, Xcyte Therapies, HemaQuest Therapeutics, Cetya Therapeutics and Sapientia Therapeutics.
Roger Gregory, PhD, Professor of Chemistry and Biochemistry, Kent State University, has been working with Arch Therapeutics since late 2011. He has provided expertise in product formulation and the relationship between the structure and properties of peptides. Dr. Gregory is a physical biochemist with over 30 years of experience in protein chemistry and analysis. His research interests include protein dynamics, protein hydration, and protein-solvent interactions. He recently returned to the Kent State faculty after serving over seven years as Chair of the Department of Chemistry. As Chair, he helped establish core facilities in genomics, proteomics, bioimaging and 3D visualization. Dr. Gregory earned his BSc and PhD in Biochemistry from the University of Sheffield, England, and performed his postdoctoral work in Protein Chemistry at the University of Minnesota.
Dr. Denman started advising Arch Therapeutics in 2012. He is a Massachusetts General Hospital Anesthesiologist, Clinical Trial Investigator and past Chief Medical Officer of Covidien and GE Healthcare.
Dr. Denman received his medical training in the United Kingdom, completing residency at St. Bartholomew’s Hospital in London, followed by a fellowship at Massachusetts General Hospital, remaining on staff. In 2000 he became Chief of Pediatric Anesthesia at the Floating Hospital for Children in Boston. During his full-time medical practice he was involved in multiple clinical trials and development of pharmaceuticals and devices. He filed and was awarded several patents while focusing on solutions for unmet clinical needs.
In 2003, he began his career at Tyco Healthcare, now Covidien, becoming the Chief Medical Officer and VP for Medical Affairs in 2007. He guided development and implementation of the medical functions throughout Covidien, built a medical affairs, clinical affairs, healthcare economics and reimbursement team; focused these functions on ensuring compliance with new regulations and driving the medical voice into all aspects of the business. In From 2010 to 2012, he was the Chief Medical Officer at GE Healthcare. In this role he strove to ensure a patient-centered culture while focusing on healthcare providers and his team was embedded in all facets of the business; R&D, clinical trials, training, compliance, business development and risk management.
He continues a clinical practice at Massachusetts General Hospital and an academic affiliation at Harvard Medical School, both in Boston. He continues to publish and has recently been granted several more patents. He is co-leader of an annual mission to Vietnam where he provides care to children and medical teaching to those who care for children.
Steve Schwaitzberg, MD, FACS, is an advisor to Arch, bringing his expertise in surgery, clinical trials, and biomaterials for hemostasis and sealing. He is Professor of and Chairman the Department of Surgery for the University at Buffalo - Jacobs School of Medicine and Biomedical Sciences. Formerly he was the is Chief of Surgery at Cambridge Health Alliance, adjunct professor at Tufts University, and Professor of surgery at Harvard Medical School. He is Past President of the Society of American Gastrointestinal Endoscopic Surgeons (SAGES), a world-class laparoscopic surgical association.
A key opinion leader, Dr. Schwaitzberg has a distinguished reputation in surgery. He was initially trained as a trauma and surgical infection expert and then became an early leader in the minimally invasive surgery (MIS) revolution. Dr. Schwaitzberg is an innovator who teaches surgical technique around the world. He has served in key leaderships positions in major surgical organizations and received international recognition as a leader in technology in the operating room and for the introduction of novel MIS technology.
Dr. Schwaitzberg is a seasoned clinical researcher who also served as the Chairman of the Tufts University School of Medicine and Medical Center institutional review Board. He has a deep interest in technology development. He is widely published and has been invited to present and teach courses around the world for over 25 years. Dr. Schwaitzberg earned an MD from Baylor College of Medicine, a MA from Harvard medical School and a BA in biology from The Johns Hopkins University.
Elaine Whitmore, PhD, brings over 25 years of extensive history in the medical products industry to Arch Therapeutics, with whom she started working in late 2010 focusing on regulatory planning and strategy. In addition to regulatory submissions, Dr. Whitmore’s experience includes development, testing, technology evaluation, and clinical planning for a variety of hemostasis products (fibrin sealants; bovine, human and recombinant thrombin products; cellulose; collagen; etc.), adhesion prevention products, and infection prevention products.
Dr. Whitmore is the author of Development of FDA-Regulated Medical Products—A Translational Approach (ASQ Quality Press, 2012) and has numerous patents for medical product technologies. Prior to becoming a product development and technology consultant, she held executive management industry positions in a variety of functions, including New Product Development, Regulatory and Clinical Affairs, Scientific Affairs, and Business Development. Dr. Whitmore received her PhD degree from Northwestern University.